3 Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks With a Strong Future Roadmap: Alkem Laboratories, Godrej Industries and Redtape

Generic formulation exporter, diversified group stake holder and footwear brand stocks give investors exposure to medicines, group businesses and footwear used every day. Volumes, pricing and margins decide how much of that demand turns into profit.

This list covers three generic formulation exporter, diversified group stake holder and footwear brand stocks: Alkem Laboratories for branded generics in India along with generic exports and a presence in international markets, Godrej Industries for chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm and Redtape for footwear, apparel and accessories sold through its own brand stores and online channels. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks?

Generic formulation exporter, diversified group stake holder and footwear brand stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three generic formulation exporter, diversified group stake holder and footwear brand stocks as of the 14 Oct 2026 close.

Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.

Why Do Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks Have a Strong Roadmap in India?

Generic formulation exporter, diversified group stake holder and footwear brand stocks have a strong roadmap in India because doctor-prescribed brands, diversified group earnings and branded footwear spending keep adding volumes for these firms. Three drivers stand out.

• Branded generics: Doctors prescribe trusted brands across therapies.
• Group strength: Chemicals and listed stakes spread earnings across sectors.
• Brand spending: Shoppers choose branded footwear and apparel.

Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline

Alkem's roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.

Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore. Operating margin was 23.20% in FY26.

Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 28.43 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Godrej Industries: Chemicals and Group Holdings Build the Next Leg

Godrej Industries' roadmap rests on chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm, with its chemical business and holdings in other group companies widening the earnings base.

Revenue grew from Rs 15,064.67 crore in FY22 to Rs 25,980.60 crore in FY26, a 72.5% rise, and FY26 revenue was 18.5% higher than FY25. FY26 net profit rose 29.8% to Rs 2,411.91 crore. Over four years, net profit rose from Rs 992.43 crore in FY22 to Rs 2,411.91 crore. In Q1 FY27, revenue grew 11.2% to Rs 6,360.30 crore. Operating margin was 26.91% in FY26.

Return on equity is 11.10%. At a P/E of 15.29 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: The P/E of 15.29 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Redtape: A Footwear Brand Anchors the Roadmap

Redtape's roadmap rests on footwear, apparel and accessories sold through its own brand stores and online channels, with store expansion supporting growth.

FY26 revenue was Rs 2,551.61 crore, 17.5% higher than FY25. FY26 net profit rose 41.5% to Rs 240.55 crore. In Q1 FY27, revenue grew 4.8% to Rs 496.42 crore, and net profit rose 15.2% to Rs 44.48 crore. Operating margin was 20.07% in FY26 and 20.50% in Q1 FY27 against 18.56% a year earlier.

Debt to equity is 0.70 and return on equity is 23.55%. FY26 operating cash flow was Rs 174.01 crore against capital expenditure of Rs 85.92 crore. Redtape paid a dividend of Rs 2 per share for FY26, a yield of 1.76%. At a P/E of 25.49 against an industry P/E of 66.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 20.50% against 20.07% for FY26, so margin stability is the figure to follow as volumes grow.

Best Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks in India: Alkem vs Godrej Industries vs Redtape on Key Financials

Among the best generic formulation exporter, diversified group stake holder and footwear brand stocks in India, Alkem ranks second on FY26 operating margin and Q1 FY27 revenue growth; Godrej Industries leads on FY26 revenue growth and FY26 operating margin; Redtape leads on FY26 net profit growth and return on equity. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen generic formulation exporter, diversified group stake holder and footwear brand stocks and shortlist generic formulation exporter, diversified group stake holder and footwear brand stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check revenue growth, operating margin and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these generic formulation exporter, diversified group stake holder and footwear brand stocks

Risks to Consider Before Investing in Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks

• Consumer demand: Spending patterns can shift sales between quarters.
• Input costs: Changes in raw material prices can affect margins.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Alkem, Godrej Industries and Redtape live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover branded generics, a diversified group and footwear. Alkem ranks second on FY26 operating margin and Q1 FY27 revenue growth; Godrej Industries leads on FY26 revenue growth and FY26 operating margin; Redtape leads on FY26 net profit growth and return on equity.

Across generic formulation exporter, diversified group stake holder and footwear brand stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the generic formulation exporter, diversified group stake holder and footwear brand stocks to buy discussed here.

FAQs on Generic Formulation Exporter, Diversified Group Stake Holder and Footwear Brand Stocks

Which are the best generic formulation exporter, diversified group stake holder and footwear brand stocks in India with a strong roadmap?

Ans. Alkem Laboratories, Godrej Industries and Redtape stand out for their roadmaps in branded generics, a diversified group and footwear. FY26 revenue growth was 13.7% at Alkem, 18.5% at Godrej Industries and 17.5% at Redtape, and return on equity ranges from 11.10% to 23.55%.

Is Alkem Laboratories a good stock to buy now?

Ans. Alkem Laboratories has a debt to equity ratio of 0.15, a return on equity of 16.66% and a P/E of 28.43 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Alkem, Godrej Industries and Redtape?

Ans. The P/E ratio is 28.43 for Alkem (industry 37.59), 15.29 for Godrej Industries (industry 36.60) and 25.49 for Redtape (industry 66.59). All of them trade below the industry multiple.

Which of these generic formulation exporter, diversified group stake holder and footwear brand stocks has the highest return on equity?

Ans. Redtape has the highest return on equity at 23.55%, followed by Alkem Laboratories at 16.66% and Godrej Industries at 11.10%.

What are the risks of investing in generic formulation exporter, diversified group stake holder and footwear brand stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Alkem, Godrej Industries and Redtape perform in Q1 FY27?

Ans. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year. Godrej Industries reported revenue of Rs 6,360.30 crore, up 11.2% year on year. Redtape reported revenue of Rs 496.42 crore, up 4.8% year on year, and net profit rose 15.2% to Rs 44.48 crore.

Do generic formulation exporter, diversified group stake holder and footwear brand stocks pay dividends?

Ans. Alkem and Redtape pay dividends. The dividend yield is 1.01% for Alkem and 1.76% for Redtape, based on dividends declared for FY26.

How can I invest in generic formulation exporter, diversified group stake holder and footwear brand stocks in India?

Ans. You can buy generic formulation exporter, diversified group stake holder and footwear brand stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.